News and Announcements
The Shivom Whitepaper
- Published April 03, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Shivom is proud to present its detailed whitepaper, discussing the challenges in the fields of genomics and medicine, and how our platform solution will tackle them.
Key Takeaways from the whitepaper:
- Shivom Vision and Purpose
-
Research & Development in the field of Genomics and DNA Data Analysis
-
Use of Blockchain Technology for Solving the DNA and Healthcare Data Identity Crises
-
Technical Components of the Shivom Platform
-
Utility of the OmiX Token
-
Eventual Roadmap for Shivom to Revolutionize Global Healthcare & Precision Medicine
-
Shivom Management Team and Innovation Council of Expert Advisors
This whitepaper aims to answer all your questions and enquiries as a contributor to the Shivom ecosystem. Check it out here!
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
